Literature DB >> 16624843

DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression.

Jamie M Margolis1, Benedikt G Schoser, Melinda L Moseley, John W Day, Laura P W Ranum.   

Abstract

Myotonic dystrophy type 2 (DM2) is caused by a CCTG expansion mutation in intron 1 of the zinc finger protein 9 (ZNF9) gene. The mean expansion size in patients is larger than for DM1 or any previously reported disorder (mean=5000 CCTGs; range=75-11 000), and similar to DM1, repeats containing ribonuclear inclusions accumulate in affected DM2 tissue. Although an RNA gain-of-function mechanism involving DM1 CUG or DM2 CCUG expansion transcripts is now well established, still debated are the potential role that flanking sequences within the DMPK 3'-UTR may have on disease pathogenesis and whether or not decreased expression of DMPK, ZNF9 or neighboring genes at these loci contribute to disease. To address these questions in DM2, we have examined the nucleic acid content of the ribonuclear inclusions and the effects of these large expansions on ZNF9 expression. Using cell lines either haploid or homozygous for the expansion, as well as skeletal muscle biopsy tissue, we demonstrate that pre-mRNAs containing large CCUG expansions are normally spliced and exported from the nucleus, that the expansions do not decrease ZNF9 expression at the mRNA or protein level, and that the ribonuclear inclusions are enriched for the CCUG expansion, but not intronic flanking sequences. These data suggest that the downstream molecular effects of the DM2 mutation are triggered by the accumulation of CCUG repeat tract alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624843     DOI: 10.1093/hmg/ddl103

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

Review 1.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

2.  Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.

Authors:  Christina Wei; Lauren Stock; Christiane Schneider-Gold; Claudia Sommer; Nikolai A Timchenko; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

Review 3.  New pathologic mechanisms in nucleotide repeat expansion disorders.

Authors:  C M Rodriguez; P K Todd
Journal:  Neurobiol Dis       Date:  2019-06-21       Impact factor: 5.996

4.  Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.

Authors:  Olayinka Raheem; Shodimu-Emmanuel Olufemi; Linda L Bachinski; Anna Vihola; Mario Sirito; Jeanette Holmlund-Hampf; Hannu Haapasalo; Yi-Ping Li; Bjarne Udd; Ralf Krahe
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 5.  Mechanisms of RNA-mediated disease.

Authors:  Jason R O'Rourke; Maurice S Swanson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

6.  A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways.

Authors:  Raphael I Benhamou; Alicia J Angelbello; Eric T Wang; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2020-01-24       Impact factor: 8.116

7.  Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Qing Yu; Sadguna Balijepalli; Carla D Frenzel-McCardell; T David Bourne; Lawrence H Phillips
Journal:  Nat Genet       Date:  2006-07-30       Impact factor: 38.330

8.  RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.

Authors:  Karlie Jones; Bingwen Jin; Polina Iakova; Claudia Huichalaf; Partha Sarkar; Christiane Schneider-Gold; Benedikt Schoser; Giovanni Meola; Ann-Bin Shyu; Nikolai Timchenko; Lubov Timchenko
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

9.  Small molecules that target the toxic RNA in myotonic dystrophy type 2.

Authors:  Lien Nguyen; JuYeon Lee; Chun-Ho Wong; Steven C Zimmerman
Journal:  ChemMedChem       Date:  2014-06-17       Impact factor: 3.466

10.  Reduction of the rate of protein translation in patients with myotonic dystrophy 2.

Authors:  Claudia Huichalaf; Benedikt Schoser; Christiane Schneider-Gold; Bingwen Jin; Partha Sarkar; Lubov Timchenko
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.